Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21062863 | 0.81 | TRPA1 (0.40) | BACE1TRPA1DRD2LMNACHRM2 | |
| SCHEMBL21062864 | 0.81 | TRPA1 (0.40) | BACE1TRPA1DRD2LMNACHRM2 | |
| SCHEMBL29352703 | 0.81 | TRPA1 (0.45) | BACE1TRPA1DRD2LMNACHRM2 | |
| SCHEMBL54919 | 0.81 | TRPA1 (0.45) | BACE1TRPA1DRD2LMNACHRM2 | |
| SCHEMBL15704720 | 0.78 | MEN1 (0.34) | ADRA2AADRA2BADRA2CCHRM3SLC6A2 | |
| SCHEMBL14292346 | 0.74 | SNCA (0.34) | — | |
| SCHEMBL30004254 | 0.74 | BACE1 (0.44) | BACE1TRPA1DRD2LMNACHRM2 | |
| SCHEMBL14261898 | 0.71 | DRD2 (0.32) | DRD2LMNACHRM2HTR1AADRA2A | |
| SCHEMBL16556384 | 0.68 | ACHE (0.33) | — | |
| SCHEMBL15215946 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0704535-B1 | Mediators suitable for the electrochemical regeneration of NADH, NADPH or analogs thereof | BAYER AG (US) | 2001-11-28 | — | — | EP | claimed |
| EP-0704535-A2 | Mediators suitable for the electrochemical regeneration of NADH, NADPH or analogs thereof | Bayer Corporation (US) | 1996-04-03 | — | — | EP | claimed |
| US-5498542-A | Electrode mediators for regeneration of NADH and NADPH | BAYER CORPORATION (US) | 1996-03-12 | — | — | US | claimed |
| JP-8100284-A | — | — | None | — | — | JP | disclosed |
| US-20230277863-A1 | Use Of Photosensitizers For Treatment Of Viral Respiratory Infections | ARENTZ JOCHEN (DE) | 2023-09-07 | — | — | US | disclosed |
| EP-0704535-B1 | Mediators suitable for the electrochemical regeneration of NADH, NADPH or analogs thereof | BAYER AG (US) | 2001-11-28 | — | — | EP | disclosed |
| JP-H08100284-A | MEDIATOR FOR ELECTROCHEMICAL REGENERATION OF NADH, NADPH OR THEIR ANALOGUE | BAYER CORP | 1996-04-16 | — | — | JP | disclosed |
| EP-0704535-A2 | Mediators suitable for the electrochemical regeneration of NADH, NADPH or analogs thereof | Bayer Corporation (US) | 1996-04-03 | — | — | EP | disclosed |
| EP-0704535-A2 | Mediators suitable for the electrochemical regeneration of NADH, NADPH or analogs thereof | Bayer Corporation (US) | 1996-04-03 | — | — | EP | disclosed |
| US-5498542-A | Electrode mediators for regeneration of NADH and NADPH | BAYER CORPORATION (US) | 1996-03-12 | — | — | US | disclosed |
| US-5498542-A | Electrode mediators for regeneration of NADH and NADPH | BAYER CORPORATION (US) | 1996-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277863-A1 | Use Of Photosensitizers For Treatment Of Viral Respiratory Infections | PPOX, TMPRSS4, TMPRSS2 | BACE1 2036/4885TRPA1 205/4885DRD2 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.